CIK 0001501989 · Accelerated filer
CytomX Therapeutics, Inc.
Sign in to watch- Ticker
- CTMX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273521219
- Phone
- 650.515.3185
- Business address
- 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-14 | Jones Elaine V Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2023-05-19 | McCarthy Sean A. CEO | Option exercise | +16,535 | $1.57 | $26K | 405,356 |
| 2023-05-19 | McCarthy Sean A. CEO | Option exercise · Stock Option (Right to Buy) | −16,535 | 119,536 | ||
| 2023-03-29 | Jones Elaine V Director | Purchase | +5,000 | $1.55 | $8K | 5,142 |
| 2023-03-22 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award | +60,000 | 140,820 | ||
| 2023-03-16 | Ogden Christopher SVP, Finance and Accounting | Sale | −516 | $1.98 | $1K | 37,772 |
| 2023-03-16 | McCarthy Sean A. CEO | Sale | −7,121 | $1.88 | $13K | 388,821 |
| 2023-03-16 | Campoy Carlos Chief Financial Officer | Sale | −1,748 | $1.98 | $3K | 38,224 |
| 2023-03-16 | ROWLAND LLOYD A General Counsel | Sale | −2,037 | $1.98 | $4K | 71,095 |
| 2023-03-16 | Landau Jeffrey B Chief Financial Officer | Sale | −1,477 | $1.98 | $3K | 69,248 |
| 2023-03-16 | Peterson Amy C. EVP, Chief Development Officer | Sale | −4,257 | $1.98 | $8K | 58,433 |
| 2023-02-02 | McCarthy Sean A. CEO | Grant or award | +105,000 | 395,942 | ||
| 2023-02-02 | McCarthy Sean A. CEO | Grant or award · Stock Option (Right to Buy) | +315,000 | 315,000 | ||
| 2023-02-02 | McCarthy Sean A. CEO | Grant or award · Performance Stock Units (PSUs) | +300,000 | 300,000 | ||
| 2023-02-02 | Landau Jeffrey B Chief Business Officer | Grant or award | +40,000 | 70,725 | ||
| 2023-02-02 | Landau Jeffrey B Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2023-02-02 | Landau Jeffrey B Chief Business Officer | Grant or award · Performance Stock Units (PSUs) | +75,000 | 75,000 | ||
| 2023-02-02 | ROWLAND LLOYD A General Counsel | Grant or award | +25,000 | 73,132 | ||
| 2023-02-02 | ROWLAND LLOYD A General Counsel | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2023-02-02 | ROWLAND LLOYD A General Counsel | Grant or award · Performance Stock Units (PSUs) | +75,000 | 75,000 |
Page 9 of 33 · 649 trades